Seres Therapeutics (NASDAQ:MCRB) Price Target Cut to $0.75 by Analysts at The Goldman Sachs Group

Seres Therapeutics (NASDAQ:MCRB) had its target price decreased by equities research analysts at The Goldman Sachs Group from $1.00 to $0.75 in a research report issued on Friday,Benzinga reports. The firm currently has a “sell” rating on the biotechnology company’s stock. The Goldman Sachs Group’s target price points to a potential upside of 8.85% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group restated a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a report on Thursday, November 14th. StockNews.com upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $4.00.

Seres Therapeutics Trading Up 7.9 %

Shares of MCRB stock traded up $0.05 during trading hours on Friday, reaching $0.69. 546,700 shares of the stock were exchanged, compared to its average volume of 1,389,521. Seres Therapeutics has a 12-month low of $0.54 and a 12-month high of $1.53. The company’s 50-day moving average price is $0.80 and its 200-day moving average price is $0.83. The firm has a market capitalization of $119.96 million, a price-to-earnings ratio of -3.00 and a beta of 2.19.

Institutional Investors Weigh In On Seres Therapeutics

A number of hedge funds have recently modified their holdings of MCRB. Avantax Advisory Services Inc. raised its position in shares of Seres Therapeutics by 170.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 28,500 shares during the last quarter. Jane Street Group LLC raised its position in shares of Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 37,866 shares during the last quarter. Virtu Financial LLC raised its position in shares of Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC raised its position in shares of Seres Therapeutics by 29.2% in the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 22,250 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after buying an additional 44,461 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.